Annexin Pharmaceuticals Ab Stock EBITDA
| ANNX Stock | SEK 0.50 0.01 1.96% |
Annexin Pharmaceuticals AB fundamentals help investors to digest information that contributes to Annexin Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Annexin Stock. The fundamental analysis module provides a way to measure Annexin Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Annexin Pharmaceuticals stock.
Annexin |
Annexin Pharmaceuticals AB Company EBITDA Analysis
Annexin Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Annexin Pharmaceuticals EBITDA | (50.28 M) |
Most of Annexin Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Annexin Pharmaceuticals AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Annexin Pharmaceuticals AB reported earnings before interest,tax, depreciation and amortization of (50.28 Million). This is 105.73% lower than that of the Healthcare sector and 150.2% lower than that of the Biotechnology industry. The ebitda for all Sweden stocks is 101.29% higher than that of the company.
Annexin EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Annexin Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Annexin Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Annexin Pharmaceuticals by comparing valuation metrics of similar companies.Annexin Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Annexin Fundamentals
| Return On Equity | -1.06 | |||
| Return On Asset | -0.57 | |||
| Current Valuation | 125.48 M | |||
| Shares Outstanding | 154.5 M | |||
| Shares Owned By Insiders | 45.17 % | |||
| Shares Owned By Institutions | 5.06 % | |||
| Price To Book | 4.90 X | |||
| EBITDA | (50.28 M) | |||
| Net Income | (52.14 M) | |||
| Cash And Equivalents | 22.77 M | |||
| Cash Per Share | 1.29 X | |||
| Debt To Equity | 1.20 % | |||
| Current Ratio | 9.56 X | |||
| Book Value Per Share | 0.20 X | |||
| Cash Flow From Operations | (45.02 M) | |||
| Earnings Per Share | (0.43) X | |||
| Target Price | 2.0 | |||
| Beta | 1.55 | |||
| Market Capitalization | 189.95 M | |||
| Total Asset | 52.79 M | |||
| Net Asset | 52.79 M |
About Annexin Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Annexin Pharmaceuticals AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Annexin Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Annexin Pharmaceuticals AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Annexin Stock Analysis
When running Annexin Pharmaceuticals' price analysis, check to measure Annexin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annexin Pharmaceuticals is operating at the current time. Most of Annexin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Annexin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annexin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Annexin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.